Mumbai, 14th August 2024: The financial statements for the first quarter of Q1 FY 25 have been released by Supriya Lifescience Ltd., a cGMP-compliant business with a strong track record in API manufacturing and a focus on products from a variety of therapeutic segments, including anti-histamine, anti-allergic, vitamin, anaesthetic, and anti-asthmatic.
Performance Highlights for Q1 FY25:
- In the first quarter of FY25, Supriya Lifescience Ltd. witnessed remarkable growth in its revenue, reporting a 21.7 % year-over-year increase, reaching Rs. 160.63 crore compared to Rs. 132.02 crore in Q1 FY24.
- EBITDA for Q1 FY25 stood at Rs. 62.54 crore, with an EBITDA Margin of 38.9%, as opposed to an EBITDA of Rs. 44.49 crore in Q1 FY24 with an EBITDA margin of 33.7%. This marks a growth of 40.6% YoY.
- The Profit After Tax (PAT) for Q1 FY25 came at Rs 44.64 crore, compared to Rs 28.51 crore in Q1 FY24.
- The PAT Margin stood at 27.8% in Q1 FY25, compared to 21.6% in Q1 FY24.
- The company has seen good growth across different therapeutic areas in Q1FY25
- European markets now contribute 51% of our business revenue up from 43% in Q4FY24 and 34% in Q1FY24.
Consolidated Financial Highlights:
| Particulars | Q1 FY25 | Q1 FY24 | YoY Growth |
| Revenues (in Rs Cr) | Rs. 160.63 | Rs. 132.02 | 21.7% |
| Gross Profit (in Rs Cr) | Rs. 112.03 | Rs.84.80 | 32% |
| EBITDA (in Rs Cr) | Rs. 62.54 | Rs. 44.49 | 40.6% |
| EBITDA Margin | 38.9% | 33.7% | +524 bps |
| PAT (in RsCr) | Rs. 44.64 | Rs. 28.51 | 56.6% |
| PAT Margin | 27.8% | 21.6% | +620 bps |
| Quarterly EPS (in Rs) | 5.54 | 3.54 | 56.5% |
Dr Saloni Wagh, Managing Director, Supriya Lifescience Ltd, commenting on the results, said, “We are engaged in discussions with a diverse range of companies, from major pharmaceutical firms to innovative enterprises, to establish partnerships for supplying tailored products. The company achieved a record capital expenditure of Rs. 146 crore in the last financial year while also enhancing its return on equity by 210 basis points
We’re proud to unveil our new R&D facility at Lote Parshuram and anticipate the completion of our Ambernath lab by early Q2FY25. These state-of-the-art centers will drive our next phase of growth, focusing on advanced product development, CMO/CDMO opportunities, and expanding our portfolio to meet evolving market needs. Moving forward, the company aims for significant growth with improved profitability.”